A three year double blind investigation of the effects of lithium carbonate on serum protein-bound iodine in manic depressive patients.
In a controlled investigation of the long-term effect of lithium on protein-bound iodine (PBI), 17 manic-depressive patients were placed on lithium for 6 months then shifted on a double blind basis to lithium (8 patients) and placebo (9 patients), and followed for a maximum of 3 years. Serum PBIs and lithium levels were evaluated initially and every 3 months thereafter. The placebo group showed no significant change in PBI during the first 6 months while still on lithium. At 9- and 12-month evaluations, a rise in serum PBI was noted. Seven placebo patients with data available displayed a mean 6-month PBI of 6.26 +/- 0.67 mug% and at 9 months 7.07 +/- 0.63 mug% (p less than 0.02). Available data for 7 placebo patients at 6 and 12 months show means of 6.30 +/- 0.66 and 7.06 +/- 0.56 mug%, respectively (p less than 0.10). Patients on lithium during the entire study had a PBI of 6.95 +/- 0.81 mug% at 6 months, which dropped to 5.76 +/- 0.36 mug% (p less than 0.05) after an average of 810 days of treatment. The placebo group showed no statistically significant change in PBI.
D000368:Aged; D001714:Bipolar Disorder / Q000097:blood / Q000188:drug therapy*; D001798:Blood Proteins / Q000378:metabolism*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007455:Iodine / Q000097:blood*; D008094:Lithium / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011485:Protein Binding; D013961:Thyroid Gland / Q000187:drug effects; D013997:Time Factors
D001798:Blood Proteins; D007455:Iodine; D008094:Lithium